Clinical Epidemiology and Ageing

Immune response to pertussis vaccine in COPD patients.

Feredj E, Wiedemann A, Krief C, Maitre B, Derumeaux G, Chouaid C, Le Corvoisier P, Lacabaratz C, Gallien S, Lelièvre JD, Boyer L Sci Rep. 2023;13(1):11654.

Exacerbation triggered by respiratory infection is an important cause of morbidity and mortality in chronic obstructive pulmonary disease (COPD) patients. Strategies aiming to preventing infection may have significant public health impact. Our previous study demonstrated decreased immunological response to seasonal flu vaccination in COPD patients, questioning the efficiency of other vaccines in this group of patients. We performed a prospective, monocenter, longitudinal study that evaluated the humoral and cellular responses upon pertussis vaccination. We included 13 patients with stable COPD and 8 healthy volunteers. No difference in circulating B and T cell subsets at baseline was noted. Both groups presented similar levels of TFH, plasmablasts and pertussis specific antibodies induction after vaccination. Moreover, monitoring T cell immunity after ex-vivo peptide stimulation revealed equivalent induction of functional and specific CD4+ T cells (IFNγ, TNFα and IL-2-expressing T cells) in both groups. Our results highlight the immunological efficiency of pertussis vaccination in this particularly vulnerable population and challenge the concept that COPD patients are less responsive to all immunization strategies. Healthcare providers should stress the necessity of decennial Tdap booster vaccination in COPD patients.

MeSH terms: Antibodies, Bacterial; Diphtheria-Tetanus-acellular Pertussis Vaccines; Humans; Immunity; Immunization, Secondary; Longitudinal Studies; Pertussis Vaccine; Prospective Studies; Vaccination; Whooping Cough
DOI: 10.1038/s41598-023-38355-8